Citations 1
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.
Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.